First Tracks Biotherapeutics (NASDAQ:TRAX) Coverage Initiated at Wedbush

Equities research analysts at Wedbush started coverage on shares of First Tracks Biotherapeutics (NASDAQ:TRAX) in a research report issued to clients and investors on Friday, MarketBeat reports. The firm set an “outperform” rating and a $30.00 price target on the stock. Wedbush’s price target indicates a potential upside of 65.20% from the company’s previous close.

Several other analysts also recently weighed in on TRAX. Barclays initiated coverage on shares of First Tracks Biotherapeutics in a research report on Wednesday. They issued an “overweight” rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on shares of First Tracks Biotherapeutics in a research report on Thursday. They issued an “overweight” rating and a $31.00 price objective on the stock. Leerink Partners initiated coverage on shares of First Tracks Biotherapeutics in a research report on Friday. They issued an “outperform” rating and a $46.00 price objective on the stock. Finally, UBS Group initiated coverage on shares of First Tracks Biotherapeutics in a research report on Tuesday, April 21st. They issued a “buy” rating and a $45.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $38.40.

First Tracks Biotherapeutics Trading Down 4.4%

Shares of NASDAQ:TRAX opened at $18.16 on Friday. First Tracks Biotherapeutics has a fifty-two week low of $14.79 and a fifty-two week high of $26.80.